JP2025506487A - Rhoキナーゼを阻害する組成物及び方法 - Google Patents
Rhoキナーゼを阻害する組成物及び方法 Download PDFInfo
- Publication number
- JP2025506487A JP2025506487A JP2024547502A JP2024547502A JP2025506487A JP 2025506487 A JP2025506487 A JP 2025506487A JP 2024547502 A JP2024547502 A JP 2024547502A JP 2024547502 A JP2024547502 A JP 2024547502A JP 2025506487 A JP2025506487 A JP 2025506487A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- larazotide
- subject
- derivative
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263308330P | 2022-02-09 | 2022-02-09 | |
| US63/308,330 | 2022-02-09 | ||
| PCT/US2023/062247 WO2023154770A1 (en) | 2022-02-09 | 2023-02-09 | Compositions and methods for inhibiting rho kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506487A true JP2025506487A (ja) | 2025-03-11 |
| JP2025506487A5 JP2025506487A5 (cg-RX-API-DMAC7.html) | 2026-02-17 |
Family
ID=87565095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024547502A Pending JP2025506487A (ja) | 2022-02-09 | 2023-02-09 | Rhoキナーゼを阻害する組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250144166A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4475867A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025506487A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119730867A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3243960A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023154770A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118873629B (zh) * | 2024-09-27 | 2024-12-10 | 北京大学口腔医学院 | 醋酸拉唑肽在制备促进成骨药物中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009047532A2 (en) * | 2007-10-12 | 2009-04-16 | Cancer Research Technology Limited | Cancer susceptibility loci |
| WO2009132050A2 (en) * | 2008-04-21 | 2009-10-29 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
| JP2020507626A (ja) * | 2017-02-10 | 2020-03-12 | イノベイト バイオファーマシューティカルズ インコーポレイテッド | 腸上皮の透過性と関連する疾患を治療する組成物及び方法 |
| WO2019183036A1 (en) * | 2018-03-19 | 2019-09-26 | Innovate Biopharmaceuticals, Inc. | Compositions and methods for potentiating immune checkpoint inhibitor therapy |
| KR20220049005A (ko) * | 2019-08-16 | 2022-04-20 | 9 미터스 바이오파마, 인코포레이티드 | 라라조타이드 제형 |
| AU2021255955A1 (en) * | 2020-04-15 | 2022-11-10 | Interlude Biopharma Co. | Larazotide derivatives comprising d-amino acids |
-
2023
- 2023-02-09 CA CA3243960A patent/CA3243960A1/en active Pending
- 2023-02-09 US US18/836,845 patent/US20250144166A1/en active Pending
- 2023-02-09 EP EP23753638.8A patent/EP4475867A4/en active Pending
- 2023-02-09 WO PCT/US2023/062247 patent/WO2023154770A1/en not_active Ceased
- 2023-02-09 JP JP2024547502A patent/JP2025506487A/ja active Pending
- 2023-02-09 CN CN202380032652.0A patent/CN119730867A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023154770A1 (en) | 2023-08-17 |
| EP4475867A1 (en) | 2024-12-18 |
| CA3243960A1 (en) | 2023-08-17 |
| EP4475867A4 (en) | 2026-02-18 |
| US20250144166A1 (en) | 2025-05-08 |
| CN119730867A (zh) | 2025-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018352221B2 (en) | Peptides and nanoparticles for intracellular delivery of mRNA | |
| Bu et al. | PERK integrates oncogenic signaling and cell survival during cancer development | |
| ES2459018T3 (es) | Formulaciones de efectores de la unión estrecha | |
| CN106661094B (zh) | 骨形态发生蛋白的治疗用途 | |
| EP3442541A1 (en) | Methods for treating cancer and inhibiting graft rejection | |
| WO2023114984A1 (en) | Tead inhibitors and uses thereof | |
| CN112543809A (zh) | 包含C/EBPα saRNA的组合疗法 | |
| JP2022521299A5 (cg-RX-API-DMAC7.html) | ||
| EP2895173B1 (en) | Combined treatment with netrin-1 interfering drug and chemotherapeutic drug | |
| US20250144166A1 (en) | Compositions and methods for inhibiting rho kinase | |
| Parrasia et al. | Targeting pancreatic ductal adenocarcinoma (PDAC) | |
| JP7583448B2 (ja) | 抗腫瘍アレナウイルスおよびアレナウイルス変異体を生産するための方法 | |
| MG Saez | Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer | |
| JP7525408B2 (ja) | ペプチドを用いる併用療法 | |
| CN116390757A (zh) | 用于治疗肿瘤的药物组合物 | |
| CN115956078A (zh) | Akt3调节剂及其使用方法 | |
| CN108601850A (zh) | 抗癌和抗炎症治疗及其方法 | |
| CN111821458A (zh) | 一种用于非小细胞肺癌治疗的药物组合物 | |
| JP5393691B2 (ja) | 急性ヒト骨髄性白血病細胞を死滅させるトロンボポエチン受容体作用薬(TpoRA) | |
| Dayanc et al. | Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is | |
| Dayanc et al. | Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue | |
| CN118217382A (zh) | 使用麦胶蛋白肽治疗癌症的套件和方法 | |
| WO2020252453A1 (en) | Membrane attack complexes and uses thereof | |
| JP7598660B2 (ja) | フラジェリン由来のtlr5アゴニストを有効成分として含む抗がん剤組成物 | |
| Zhao et al. | Zolbetuximab combined with chemotherapy in a patient with CLDN18. 2-positive advanced gastric cancer undergoing hemodialysis: a case report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20250313 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20250313 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260206 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260206 |